肝硬化并发症治疗进展
综述总结肝硬化并发症治疗进展:非选择性β受体阻滞剂可预防临床显著门脉高压患者失代偿;高危急性静脉曲张出血(Child-Pugh 10-13分或8-9分伴内镜活动性出血)优先TIPS改善死亡率;胃底静脉曲张出血可用逆行经静脉闭塞和/或氰基丙烯酸酯注射替代TIPS;腹水、肝肾综合征、肝性脑病治疗亦有更新。
要点
- 非选择性β受体阻滞剂可预防临床显著门脉高压患者失代偿,改变基于静脉曲张的旧范式。
- 高危急性静脉曲张出血者优先TIPS改善死亡率,已成为许多中心的标准治疗。
- 胃底静脉曲张出血可用逆行经静脉闭塞和/或氰基丙烯酸酯注射替代TIPS。
核心结论
- 肝硬化分代偿与失代偿两期,生存率因分期而异;非选择性β受体阻滞剂可预防临床显著门脉高压患者失代偿。
- 高危急性静脉曲张出血患者优先TIPS改善死亡率,已成为许多中心的标准治疗。
- 胃底静脉曲张出血可用逆行经静脉闭塞和/或氰基丙烯酸酯注射替代TIPS。
- 腹水患者TIPS可能更早使用;长期白蛋白用于无并发症腹水预后改善尚在评估中。
- 肝肾综合征一线治疗为特利加压素联合白蛋白;肝性脑病一线乳果糖、二线利福昔明。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 肝硬化分代偿与失代偿两期,失代偿以腹水、静脉曲张出血和肝性脑病为定义,生存率因分期而异。
- 非选择性β受体阻滞剂可预防临床显著门脉高压患者失代偿,改变基于静脉曲张的旧范式。
- 高危急性静脉曲张出血(Child-Pugh 10-13分或8-9分伴内镜活动性出血)优先TIPS改善死亡率,已成为许多中心的标准治疗。
- 胃底静脉曲张出血可用逆行经静脉闭塞(有胃肾分流者)和/或氰基丙烯酸酯注射替代TIPS。
- 腹水患者新兴证据提示TIPS可能更早使用;长期白蛋白用于无并发症腹水预后改善尚在评估,验证性研究进行中。
关键数值与推荐
- 高危急性静脉曲张出血定义为Child-Pugh评分10-13分或Child-Pugh评分8-9分且内镜见活动性出血。
- 肝肾综合征为肝硬化急性肾损伤最少见病因,一线治疗为特利加压素联合白蛋白。
- 肝性脑病一线治疗为乳果糖,二线为利福昔明;L-鸟氨酸L-天冬氨酸和白蛋白等新疗法需进一步评估。
临床怎么用
- 临床显著门脉高压患者可用非选择性β受体阻滞剂预防失代偿。
- 高危急性静脉曲张出血患者优先TIPS,已成为许多中心的标准治疗。
- 胃底静脉曲张出血有胃肾分流者可用逆行经静脉闭塞,和/或氰基丙烯酸酯注射替代TIPS。
- 肝肾综合征一线治疗为特利加压素联合白蛋白;肝性脑病一线乳果糖、二线利福昔明。
- 长期白蛋白用于无并发症腹水预后改善尚在评估,验证性研究进行中。
局限性
- 长期白蛋白用于无并发症腹水预后改善尚在评估,验证性研究进行中。
- L-鸟氨酸L-天冬氨酸和白蛋白等新疗法需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis consists of 2 main stages: compensated and decompensated, the latter defined by the development/presence of ascites, variceal hemorrhage, and hepatic encephalopathy. The survival rate is entirely different, depending on the stage. Treatment with nonselective β-blockers prevents decompensation in patients with clinically significant portal hypertension, changing the previous paradigm based on the presence of varices. In patients with acute variceal hemorrhage at high risk of failure with standard treatment (defined as those with a Child-Pugh score of 10-13 or those with a Child-Pugh score of 8-9 with active bleeding at endoscopy), a pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) improves the mortality rate and has become the standard of care in many centers. In patients with bleeding from gastrofundal varices, retrograde transvenous obliteration (in those with a gastrorenal shunt) and/or variceal cyanoacrylate injection have emerged as alternatives to TIPS. In patients with ascites, emerging evidence suggests that TIPS might be used earlier, before strict criteria for refractory ascites are met. Long-term albumin use is under assessment for improving the prognosis of patients with uncomplicated ascites and confirmatory studies are ongoing. Hepatorenal syndrome is the least common cause of acute kidney injury in cirrhosis, and first-line treatment is the combination of terlipressin and albumin. Hepatic encephalopathy has a profound impact on the quality of life of patients with cirrhosis. Lactulose and rifaximin are first- and second-line treatments for hepatic encephalopathy, respectively. Newer therapies such as L-ornithine L-aspartate and albumin require further assessment.
引用
- Abraldes JG, Caraceni P, Ghabril M, et al. Update in the Treatment of the Complications of Cirrhosis. Clin Gastroenterol Hepatol. 2023. PMID: 36972759. doi:10.1016/j.cgh.2023.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。